Tirzepatide and Lithium Toxicity: A Case

A case report published on 1 June 2026 in the Journal of Clinical Psychopharmacology describes a patient with previously stable bipolar I disorder who developed lithium toxicity severe enough to require hemodialysis after starting tirzepatide^[1]. The patient had been on a steady lithium regimen without prior toxicity episodes. The report, from a Mayo Clinic team led by Patarroyo-Rodriguez, adds to a small but growing body of evidence that GLP-1 receptor agonists can disrupt lithium clearance in ways clinicians and patients need to anticipate.

What the case report describes

The full text is behind a journal paywall, so the clinical granularity (exact doses, lab timelines, renal markers) is not available for independent verification at the time of writing. What the bibliographic record and the broader Mayo Clinic research programme confirm is this: the patient was on stable lithium therapy for bipolar I disorder, began tirzepatide, and developed lithium toxicity that progressed to the point where hemodialysis was necessary to clear the drug. That is a more severe outcome than any previously published case in this drug-interaction space.

For context, an earlier case from the same institution described a 23-year-old male with schizoaffective disorder whose lithium level rose from 0.9 to 1.7 mEq/L four days after switching from semaglutide to tirzepatide. That patient was managed with intravenous fluids and a lithium dose reduction^[2]. The new case escalated beyond fluid resuscitation to hemodialysis, which is typically reserved for lithium levels above 2.5 mEq/L or when renal function is compromised.

Why GLP-1 drugs and lithium interact

Lithium has a narrow therapeutic window. The therapeutic range sits between 0.6 and 1.2 mEq/L; toxicity begins above 1.5 mEq/L and can be life-threatening above 2.5 mEq/L. Anything that shifts the body's handling of lithium (hydration, kidney function, absorption rate) can tip a stable patient into danger.

Tirzepatide, like other GLP-1 receptor agonists, delays gastric emptying, suppresses appetite, and commonly causes nausea, vomiting, and diarrhoea. The Mounjaro prescribing information warns that the drug "has the potential to impact the absorption of concomitantly administered oral medications" and flags postmarketing reports of acute kidney injury linked to dehydration from gastrointestinal side effects^[3]. A three-patient case series from Mayo Clinic (Al-Soleiti et al., 2025) documented that semaglutide raised lithium levels to toxic range in two of three patients despite stable renal function and no other medication changes^[4]. The proposed mechanisms include dehydration from reduced oral intake and GI losses, delayed gastric emptying altering lithium absorption kinetics, and possible changes in renal lithium handling.

What this does not tell us

This is a single case report, not a systematic study. We do not know how common this interaction is, whether tirzepatide carries a higher risk than semaglutide (the earlier cases involved semaglutide or a switch between agents), or whether certain patient populations are more vulnerable. The full text of the case has not been independently reviewed here because it sits behind a paywall. Hemodialysis for lithium toxicity is a well-established emergency intervention, not a novel procedure; the novelty is the trigger.

What clinicians and patients should watch for

The published case literature, now spanning at least four patients across three reports from the same research group, converges on a practical recommendation: when starting or switching a GLP-1 receptor agonist in a patient taking lithium, check lithium levels more frequently in the first weeks, monitor for early signs of toxicity (tremor, confusion, nausea beyond what the GLP-1 drug itself causes, unsteadiness), and reassess hydration status. The Al-Soleiti case series recommends baseline renal function and lithium levels before initiating any GLP-1 agonist, with increased monitoring frequency during the titration period^[4].

Lithium toxicity symptoms can overlap with the gastrointestinal side effects of tirzepatide itself (nausea, vomiting), which makes the interaction easy to miss. If a patient on lithium starts tirzepatide and develops worsening nausea, tremor, or confusion, a lithium level check is the minimum response.

Where this fits on PeptideMethods

This case report sits in the broader safety picture we track on the tirzepatide page. The Mounjaro label already warns about dehydration-related acute kidney injury and delayed gastric emptying affecting oral drug absorption. The lithium interaction is not yet in the label's drug interactions section, but the accumulating case literature from Mayo Clinic suggests it may warrant inclusion. For readers on lithium who are considering or already using a GLP-1 receptor agonist, this is a conversation to have with the prescribing clinician before the next dose change.